Pancrelipase controlled-release - Digestive Care

Drug Profile

Pancrelipase controlled-release - Digestive Care

Alternative Names: PANCRECARB® MS-16; Pancrelipase delayed release capsules - Digestive Care; Pertzye; Pertzyme

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Digestive Care
  • Developer Chiesi USA; Digestive Care
  • Class Pancreatic enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency

Most Recent Events

  • 14 Jul 2017 Registered for Exocrine pancreatic insufficiency (In adolescents, In adults, In children, In infants) in USA (PO)
  • 01 Dec 2016 Mayo Clinic and Digestive Care initiate enrolment in a phase I/II trial for Exocrine pancreatic insufficiency (unresectable pancreatic cancer associated) in USA (NCT02985801)
  • 12 Oct 2016 Launched for Exocrine pancreatic insufficiency (In infants) in USA in October 2016 (PO, 4000 USP lipase units/capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top